Continuing their efforts to head off bioterrorism, the feds awarded hefty grants that will benefit a pair of West Coast firms in their separate bids for a vaccine against Francisella tularensis, the fast-moving bug that causes tularemia - the inhaling of which leads to a deadly form of pneumonia. (BioWorld Today)

Mixed news from a Phase II study testing its lupus drug sent shares of Human Genome Sciences Inc. into a tailspin, but the company plans to push ahead with development based on a clearly identified target patient group and a dose that works for it. (BioWorld Today)